Physician profile
Hamida Hemani
NPI 1164425518
$8,218.38
in general payments reported to CMS, 2019-2025
27 companies · $1,192 in 2025
The $1,192 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,507 · 2020: $146 · 2021: $36.00 · 2022: $532 · 2023: $965 · 2024: $1,840 · 2025: $1,192.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,762 · Entertainment: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,761.88 |
| Entertainment | $235.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $2,805.62 | 2019-2021 | |
| Visioneering Technologies, INC. | $1,000.00 | 2024 | |
| Sun Pharmaceutical Industries INC. | $821.26 | 2023-2025 | Cequa |
| Alcon Vision LLC | $714.33 | 2019-2025 | Total30, Precision7, Precision 1 |
| Bausch & Lomb Americas INC. | $284.78 | 2022-2024 | Miebo |
| Optos, INC. | $235.10 | 2023-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $209.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $165.13 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $146.17 | 2025 | |
| Johnson & Johnson Vision Care, INC. | $145.40 | 2023 | Acuvue |
| Amgen INC. | $143.28 | 2025 | Tepezza |
| Shire North American Group INC | $130.08 | 2019 | |
| Glaukos Corporation | $125.11 | 2025 | Idosetr |
| Carl Zeiss Meditec USA, INC. | $123.41 | 2023 | |
| Abbvie INC. | $123.28 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $121.86 | 2025 | Izervay |
| Alexion Pharmaceuticals, INC. | $121.86 | 2025 | Ultomiris |
| Lkc Technologies, INC. | $119.21 | 2023 | |
| Dompe US, INC. | $116.74 | 2024 | Oxervate |
| Biotissue Holdings INC. | $100.00 | 2024 | |
| Sight Sciences, INC. | $100.00 | 2019 | |
| Harrow Eye, LLC | $98.55 | 2025 | Vevye |
| Tarsus Pharmaceuticals, INC. | $94.25 | 2024 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $90.68 | 2019 | |
| Alcon Research LLC | $37.96 | 2019 | |
| Abb Con-Cise Optical Group LLC | $37.83 | 2019 | |
| Quidel Corporation | $7.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamida Hemani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.